Trials / Completed
CompletedNCT03499444
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
A Phase 1, Open-label, Safety and Pharmacokinetic Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- pharmaand GmbH · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 open-label, dose-escalation, safety and pharmacokinetic study of rucaparib administered twice daily (BID) to Japanese patients with a solid tumor who have failed previous standard treatment for their cancer. A recommended dose of rucaparib for Japanese patients will be determined in a dose-escalation portion and then further evaluated in a dose-expansion portion of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rucaparib | Rucaparib will be administered twice daily |
Timeline
- Start date
- 2018-02-06
- Primary completion
- 2019-06-18
- Completion
- 2022-04-13
- First posted
- 2018-04-17
- Last updated
- 2023-06-09
Locations
3 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03499444. Inclusion in this directory is not an endorsement.